Search for a trial

A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects

To provide clinical management and, if required, treatment to subjects who at their concluding HPV-015 study visit displayed normal cervical cytology but tested positive for oncogenic HPV infection or who were pregnant at their concluding visit of…

Simplified monitoring of post-treatment CIN2/3 women by molecular testing for hrHPV and methylation markers

Our primary objective is to determine whether testing for molecular markers, i.e. hrHPV, methylationmarkers , i.a. CADM1/MAL and combinations thereof, yields a higher sensitivity and specificity for the detection of CIN2/3 or cancer after treatment…

Discovery of biomarkers for cervical neoplasia by genome-wide gene-expression profiling

To identify molecular alterations associated with cervical tumorigenesis, that could be used as biomarker for improving detection and differentiation between cervical cancer, cervical intraepithelial neoplasia and normal cervical tissue.

Validation of the dry Evalyn Brush, an improved cervicovaginal self-sampling device for HPV detection

This study will be conducted to determine the overall hr-HPV agreement between self-sampled cervicovaginal smear (Evalyn Brush) and physician-obtained samples taken by a trained physician (liquid based cervical smear) in a screening population. The…

A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals* HPV 16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above.

* To demonstrate efficacy of the candidate vaccine in the prevention of (1) persistent infection (6-month definition) with HPV-16 or HPV-18 (by polymerase chain reaction [PCR]) and/or (2) histopathologically-confirmed CIN1+ associated with HPV-16 or…